Given that more than 40% of Indian adults are struggling with obesity and diabetes, affordable weight-loss drugs are expected ...

Viking Therapeutics, Inc. ("Viking") , a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced the initiation of ...

In a stunning premarket performance on Wednesday, Sana Biotechnology, Inc. (NASDAQ: SANA) saw its stock price soar by +256.36% to reach $5.88, a dramatic rise that has left analysts and investors ...

A range of GLP-1 weight loss drugs are currently on the market. What are they, what do they do, and where are they available?

Weight-loss medication like Semaglutide and Tirzepatide has seen a rise in demand, causing a boom in sales. This exploding ...

Type 2 diabetes is a chronic condition that affects the body’s ability to regulate blood sugar levels. For many patients, ...

Glucagon-like peptide-1 (GLP-1) analogs also known as incretin mimetics are class of drugs indicated for type-2 diabetes mellitus to lower the blood sugar level Mr. Shah Coherent Market Insights Pvt.

NEW YORK, NY, USA I January 07, 2025 I Metsera, Inc., a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and metabolic diseases, today announced ...

Shares of Sana Biotechnology (NASDAQ:SANA) rallied 270% post-market on positive results from a study of the transplantation ...

For adults with overweight or obesity without diabetes, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are efficacious ...

Discover how North Dakota is leading the way by covering Ozempic for weight loss under ACA plans, making it the first U.S.

First-in-Human Study Provides Evidence that Sana’s Hypoimmune (HIP) Technology Enables Transplanted Islet Cells to Avoid Immune Rejection and ...